» Authors » Susana Gomez-Olles

Susana Gomez-Olles

Explore the profile of Susana Gomez-Olles including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 119
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Boada-Perez M, Berastegui C, Erro M, Ussetti P, Crespo E, Donadeu L, et al.
Front Immunol . 2025 Feb; 15:1445553. PMID: 39911579
Introduction: Risk stratification for CMV infection in lung transplantation (LT) currently relies on determining donor and recipient CMV IgG before transplantation. However, it has been observed that some patients who...
2.
Grando L, Boada M, Faner R, Gomez-Olles S, Ruiz V, Bohils M, et al.
Transpl Int . 2024 Nov; 37:12979. PMID: 39588198
The pulmonary microbiome has emerged as a significant factor in respiratory health and diseases. Despite the sterile conditions maintained during lung perfusion (EVLP), the use of antibiotics in the perfuse...
3.
Donadeu L, Gomez-Olles S, Casanova F, Torija A, Lopez-Meseguer M, Boada-Perez M, et al.
Front Immunol . 2024 Oct; 15:1463769. PMID: 39439787
Introduction: Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus...
4.
Boada-Perez M, Ruiz de Miguel V, Erro M, Ussetti P, Aguilar M, Castejon R, et al.
Front Immunol . 2024 May; 15:1382459. PMID: 38799459
Introduction: Trough blood levels (C) of tacrolimus are used to adjust drug dosage, but they do not consistently correlate with clinical outcomes. Measurement of residual gene expression of nuclear factor...
5.
Revilla-Lopez E, Ruiz de Miguel V, Lopez-Meseguer M, Berastegui C, Boada-Perez M, Mendoza-Valderrey A, et al.
Front Med (Lausanne) . 2023 Feb; 10:1079317. PMID: 36817769
Background: Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM...
6.
Sanchez-Diez S, Munoz X, Ojanguren I, Romero-Mesones C, Espejo D, Villar A, et al.
J Allergy Clin Immunol Pract . 2022 Jul; 10(9):2414-2423. PMID: 35788062
Background: YKL-40 (chitinase 3-like-1) and Krebs von den Lungen-6 (KL-6) are 2 promising biomarkers that may have an important role in the management of interstitial lung diseases (ILD). Objective: The...
7.
Monforte V, Ussetti P, Castejon R, Sintes H, Perez V, Laporta R, et al.
Arch Bronconeumol . 2022 Jun; 57(11):690-696. PMID: 35699006
Introduction: Immune cell functional assay (ImmuKnow®) is a non-invasive method that measures the state of cellular immunity in immunosuppressed patients. We studied the prognostic value of the assay for predicting...
8.
Ojanguren A, Santamaria M, Milla-Collado L, Fraile C, Gatius-Caldero S, Puy S, et al.
Arch Bronconeumol . 2022 Jun; 57(7):479-489. PMID: 35698954
Background: In lung transplantation (LT), the length of ischemia time is controversial as it was arbitrarily stablished. We ought to explore the impact of extended cold-ischemia time (CIT) on ischemia-reperfusion...
9.
Monforte V, Sintes H, Ussetti P, Castejon R, Perez V, Laporta R, et al.
Arch Bronconeumol . 2022 Mar; 58(8):614-617. PMID: 35312499
No abstract available.
10.
Saez-Gimenez B, Clofent D, Lopez Meseguer M, Bravo Masgoret C, Monforte V, Berastegui C, et al.
Respir Med . 2021 Sep; 188:106584. PMID: 34560353
Background: Venous thromboembolism (VTE) is a major complication after lung transplantation (LT). However, its pathophysiology remains unknown, and coagulation profiles have yet to be described. Objective: The aim of this...